---
title: "Vyndamax (tafamidis) in transthyretin amyloid cardiomyopathy: Pharmacology questions"
description: "Pharmacology questions on Vyndamax (tafamidis) in transthyretin amyloid cardiomyopathy, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: How does Vyndamax work (mechanism of action)? Vyndamax: how much TTR stabilization does tafamidis achieve at the approved dose? How is Vyndamax metabolized and eliminated? What is the half-life of Vyndamax? 3 further questions follow. 7 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/pharmacology"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Vyndamax (tafamidis) in transthyretin amyloid cardiomyopathy: Pharmacology questions

Manufacturer: Pfizer Inc  
Prescribing information: [Vyndaqel and Vyndamax](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685)

## Mechanism

<a id="vyndamax-mechanism"></a>

### How does Vyndamax work (mechanism of action)?

> “Tafamidis is a selective stabilizer of TTR. Tafamidis binds to TTR at the thyroxine binding sites, stabilizing the tetramer and slowing dissociation into monomers, the rate-limiting step in the amyloidogenic process.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=Tafamidis%20is%20a%20selective%20stabilizer,step%20in%20the%20amyloidogenic%20process.)

> “Tafamidis is a disease-modifying therapy that inhibits cardiac amyloidosis by selectively stabilizing TTR<sup>1</sup>”

Source: [VYNDAMAX: TTR Stabilization: How VYNDAMAX® (tafamidis) Works | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-vyndamax/how-vyndamax-works#:~:text=Tafamidis%20is%20a%20disease%2Dmodifying%20therapy%20that%20inhibits%20cardiac%20amyloidosis%20by%20selectively%20stabilizing)

> “Stabilized TTR can continue to circulate naturally to perform critical biologic functions<sup>3</sup>”

Source: [VYNDAMAX: TTR Stabilization: How VYNDAMAX® (tafamidis) Works | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-vyndamax/how-vyndamax-works#:~:text=Stabilized%20TTR%20can%20continue%20to%20circulate%20naturally%20to%20perform%20critical%20biologic)

<a id="vyndamax-ttr-stabilization"></a>

### Vyndamax: how much TTR stabilization does tafamidis achieve at the approved dose?

> “At the approved dose, tafamidis achieved ≥96% stabilization in vitro in pooled wild-type TTR human plasma samples<sup>4||</sup>”

Source: [VYNDAMAX: TTR Stabilization: How VYNDAMAX® (tafamidis) Works | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-vyndamax/how-vyndamax-works#:~:text=At%20the%20approved%20dose%2C%20tafamidis,pooled%20wild%2Dtype%20TTR%20human%20plasma)

> “The analysis was not designed to make conclusions on clinical relevance of greater stabilization on cardiovascular outcomes”

Source: [VYNDAMAX: TTR Stabilization: How VYNDAMAX® (tafamidis) Works | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-vyndamax/how-vyndamax-works#:~:text=The%20analysis%20was%20not%20designed%20to%20make%20conclusions%20on,greater%20stabilization%20on%20cardiovascular%20outcomes)

> “The approved dosage studied was 80 mg of tafamidis meglumine once daily.<sup>3,4</sup>”

Source: [VYNDAMAX: TTR Stabilization: How VYNDAMAX® (tafamidis) Works | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-vyndamax/how-vyndamax-works#:~:text=The%20approved%20dosage%20studied%20was%2080%20mg%20of%20tafamidis%20meglumine%20once)

> “In vitro stabilization, assessed via subunit exchange in plasma at dose-relevant concentrations (Nelson et al), demonstrated ≥96% stabilization. An estimated 92% tetramer stabilization was derived from an integrated model-based analysis combining in vitro binding affinities with data from ATTR-ACT (Tess et al).<sup>3,4</sup>”

Source: [VYNDAMAX: TTR Stabilization: How VYNDAMAX® (tafamidis) Works | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-vyndamax/how-vyndamax-works#:~:text=In%20vitro%20stabilization%2C%20assessed%20via,data%20from%20ATTR%2DACT%20%28Tess%20et)

> “Tafamidis FDA-approved dose (80 mg once daily) yields a mean peak plasma concentration of ~28 μM<sup>2,4</sup>”

Source: [VYNDAMAX: TTR Stabilization: How VYNDAMAX® (tafamidis) Works | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-vyndamax/how-vyndamax-works#:~:text=Tafamidis%20FDA%2Dapproved%20dose%20%2880%20mg,peak%20plasma%20concentration%20of%20~28)

> “The study evaluated various concentrations ranging from 1-30 μM. Tafamidis reached mean peak plasma concentration at ~28 μM.<sup>4</sup>”

Source: [VYNDAMAX: TTR Stabilization: How VYNDAMAX® (tafamidis) Works | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-vyndamax/how-vyndamax-works#:~:text=The%20study%20evaluated%20various%20concentrations,peak%20plasma%20concentration%20at%20~28)

> “VYNDAQEL stabilized both the wild-type TTR tetramer and the tetramers of 14 TTR variants tested clinically after once-daily dosing. Tafamidis also stabilized the TTR tetramer for 25 variants tested ex vivo.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=VYNDAQEL%20stabilized%20both%20the%20wild%2Dtype,25%20variants%20tested%20ex%20vivo.)

Note: The ≥96% figure is an in vitro measurement in plasma at dose-relevant tafamidis concentrations (the study evaluated 1 to 30 μM; the page gives a mean peak plasma concentration of about 28 μM for tafamidis meglumine 80 mg once daily, VYNDAQEL). The 92% figure is derived from a model-based analysis, as the fourth passage states.

## Pharmacokinetics

<a id="vyndamax-metabolism"></a>

### How is Vyndamax metabolized and eliminated?

> “The metabolism of tafamidis has not been fully characterized. However, glucuronidation has been observed.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=The%20metabolism%20of%20tafamidis%20has,However%2C%20glucuronidation%20has%20been%20observed.)

> “After a single oral dose of tafamidis meglumine 20 mg, approximately 59% of the dose was recovered in feces (mostly as the unchanged drug) and approximately 22% of the dose was recovered in urine (mostly as the glucuronide metabolite).”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=After%20a%20single%20oral%20dose,%28mostly%20as%20the%20glucuronide%20metabolite%29.)

<a id="vyndamax-half-life"></a>

### What is the half-life of Vyndamax?

> “The mean half-life of tafamidis is approximately 49 hours. The apparent oral clearance of tafamidis meglumine is 0.228 L/h (0.263 L/h for tafamidis). The degree of drug accumulation at steady state after repeated tafamidis daily dosing is approximately 2.5-fold greater than that observed after a single dose.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=The%20mean%20half%2Dlife%20of%20tafamidis,observed%20after%20a%20single%20dose.)

<a id="vyndamax-absorption"></a>

### How quickly is Vyndamax absorbed?

> “Median tafamidis peak concentrations occurred within 4 hours following dosing.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=Median%20tafamidis%20peak%20concentrations%20occurred%20within%204%20hours%20following%20dosing.)

<a id="vyndamax-protein-binding"></a>

### How much of Vyndamax is bound to plasma proteins?

> “The apparent steady state volume of distribution of tafamidis meglumine is 16 liters and 18.5 liters for tafamidis. Plasma protein binding of tafamidis is >99% in vitro. Tafamidis primarily binds to TTR.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=The%20apparent%20steady%20state%20volume,Tafamidis%20primarily%20binds%20to%20TTR.)

## Components

<a id="vyndamax-inactive-ingredients"></a>

### What are the inactive ingredients in Vyndamax?

> “Tafamidis 61-mg soft gelatin capsule for oral use contains a white to pink colored suspension of tafamidis 61 mg and the following inactive ingredients: ammonium hydroxide 28%, butylated hydroxytoluene, gelatin, glycerin, iron oxide (red), polyethylene glycol 400, polysorbate 20, povidone (K-value 90), polyvinyl acetate phthalate, propylene glycol, sorbitol, and titanium dioxide.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=Tafamidis%2061%2Dmg%20soft%20gelatin%20capsule,glycol%2C%20sorbitol%2C%20and%20titanium%20dioxide.)

## Related pages
- [Medical information: Vyndamax (tafamidis): Transthyretin amyloid cardiomyopathy](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy)
- [Indication](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/safety)
- [Specific populations](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/guidelines)
